Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/42710
Title: Near-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHa
Other Titles: Altura quase normal em pacientes com hiperplasia adrenal congênita tratados com a combinação de GH e GnRHa
Authors: Longui, Carlos Alberto
Kochi, Cristiane
Calliari, Luis Eduardo Procopio [UNIFESP]
Modkovski, Maria Barcellos Rosa
Soares, Marisa
Alves, Erica Ferreira
Prudente, Fernanda Vilas Boas
Monte, Osmar
Universidade Federal de São Paulo (UNIFESP)
Keywords: GH
GnRHa
congenital adrenal hyperplasia
height
growth recovery
Issue Date: 1-Nov-2011
Publisher: Sbem-soc Brasil Endocrinologia & Metabologia
Citation: Arquivos Brasileiros De Endocrinologia E Metabologia. Rio De Janeiro, Rj: Sbem-soc Brasil Endocrinologia & Metabologia, v. 55, n. 8, p. 661-664, 2011.
Abstract: Introduction: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. Objectives: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. Subjects and methods: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m(2)/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. Results: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. Conclusion: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty. Arq Bras Endocrinol Metab. 2011;55(8):661-4
URI: http://repositorio.unifesp.br/11600/42710
ISSN: 0004-2730
Other Identifiers: http://dx.doi.org/10.1590/S0004-27302011000800023
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.